41 results about "Paratope" patented technology

The amino acid sequences of paratope regions involved in internalizing function of an anti-mortalin antibody into tumor cells were determined for the L-chain and H-chain variable regions of cellular internalizing anti-mortalin antibodies and non-internalizing anti-mortalin antibodies. Cancer-cell-specific drug delivery is provided by using the mortalin-binding activity of a single-chain antibody (scFv) wherein L-chain and H-chain variable regions both having the paratope region are linked together via a peptide linker. Also, the sequence of 6 amino acids of an epitope to be recognized by an anti-mortalin antibody having the internalizing function was determined. With the use of an expression vector comprising a nucleic acid that encodes the epitope, an agent for accelerating internalization of a mortalin antibody, a drug bound thereto, and the like into cancer cells is provided.

The invention relates to a fracture contraposition machine, which is characterized in that a lead screw neck is sleeved in a shaft hole at a main supporting plate; a lead screw nut is fixedly connected with an auxiliary supporting plate; one end of a guiding bar is fixed at the main supporting plate while the other end interpenetrates in a guide sleeve connected with the auxiliary supporting plate; a concave annular sidestep is arranged at each inner side of each upper central section of the main and auxiliary supporting plates respectively; an arc guide strip hole is arranged on the annular sidestep; an annular angle-adjusting disk is wedged at the annular sidestep; a guidepost pin is arranged in the arc guide strip hole with the lower end sleeved on the angle-adjusting disk; a regulating gear meshed with the sawteeth at the edge of the angle-adjusting disk is arranged in a gear hole at the supporting plate; a steel nail hanger or a clamping device is arranged in the arc strip hole of the angle-adjusting disk; a retaining sleeve frame is arranged at the lower part of the main or auxiliary supporting plate. The invention has the advantages that the contraposition error rate is very low; the invention has strong reliability to help patients recover completely; the complete cure rate is up to 95%; the surgery time and sealing time are both shortened by more than one third; the invention not only lightens the suffering of patients but also saves the cost for medical service.

The present invention relates to neutralizing anti-HIV-1 antibodies, particularly to mAb 4E10-IgG1, which has an HIV-1 neutralizing potency comparable to the one of mAb 2F5 and 2G12. 4E10-IgG1 binds to a novel conserved epitope (NWFDIT) C-terminal of the ELDKWA epitope recognized by 2F5.1 appears that both epitopes are cryptic epitopes within a region that may be accessible in a virus-cell fusion intermediate state only. 4E10-IgG1 potently neutralizes tissue culture adapted strains but also primary isolates of different clades, including A, B, C, D, and E, inclusing viruses that were found to be resistant to 2F5. None of the tested isolates was resistant to both anti-gp41-antibodies. The invention therefore also relates to peptides containing the 4E10 epitope and to compositions made thereof, as well as to anti-idiotypic antibodies that are reactive with the paratope of 4E10-IgG1, to compositions containing an antiidiotypic antibody optionally in combination with a peptide containing the 4E10 epitope, and to anti-HIV-1 compositions comprising 4E10-IgG1, optionally in combination with another neutralizing antibody such as 2F5 and/or 2G12.

Intermolecular binding can be detected by formation of a “paratope” which results in an immediate generation of a signal. The substances to be tested for interaction are bound to demitopes, wherein said demitopes are components of a paratope which binds a reporter which provides said signal when bound. Known interactions measured in this way can also be employed to screen for compounds which interfere with the interactions. In addition to testing for individual interactions, the interaction of a compound with a library or library×library interactions can also be determined and the effect of potentially interfering substances evaluated.

The invention relates to a mode identification method based on artificial immune antigen-antibody binding energy. The mode identification method based on the artificial immune antigen-antibody binding energy is a process for identifying antibody by antigen in an immune system, actually is a binding process of chemical bonds of antibody paratope and antigen epitope. Identification effects depend on the binding energy quantity of the chemical bonds. Under inspiration of the binding process, the overall identification, namely the primary mode identification performed by calculating the affinity between the antibody paratope and the antigen epitope, and the secondary mode identification, namely the local identification performed according to the binding energy quantity of the local binding site of the chemical bonds, are realized sequentially. The mode identification method based on the artificial immune antigen-antibody binding energy includes the steps: (1) calculating the affinity between the antibody paratope and the antigen epitope by utilizing the Euclidean distance, and performing the primary mode identification according to the affinity size; (2) determining matched parameters of the local binding energy according to variously typical categorical data; (3) performing the secondary mode identification for the antigen epitope by the antibody paratope according to the local binding energy quantity, and simply and effectively completing antigen epitope identification under the combined actions of the overall identification and the local identification.

AXL-specific antibodies and uses therefor are described, including monoclonal and single domain antibodies. Such antibodies bind to cell surface expressed human AXL at an epitope in an immunoglobulin-like (IgL) domain of the AXL ectodomain. The antibody may be used in an antibody-drug conjugate (ADC), for example in the treatment, detection or staging of cancer. The antibody may be biparatopic.

The invention provides a recombinant fusion protein. The recombinant fusion protein comprises a CD24 antibody or an antibody fragment thereof, wherein at least one paratope of the CD24 antibody or the antibody fragment thereof is linked to an extracellular Ig-like domain of a signal regulatory protein (SIRP) at the N end of a heavy chain or a light chain forming the paratope through a linker, and the recombinant fusion protein can be combined with CD47, CD24 and FcR at the same time. The invention further provides nucleic acid molecules encoding the recombinant fusion protein, expression vectors comprising the nucleic acid molecules, methods for preparing the recombinant fusion protein, and methods for treating diseases associated with CD47 and/or CD24 overexpression by using the recombinant fusion protein.

The invention provides a recombinant fusion protein. The recombinant fusion protein comprises a PD-L1 antibody or an antibody fragment thereof, a complementary position of the PD-L1 antibody or the antibody fragment thereof is connected with an extracellular Ig-like domain of a signal regulatory protein (SIRP) at an N end of a heavy chain variable region or a light chain variable region forming the complementary position through a linker, and the recombinant fusion protein can be simultaneously combined with CD47, PD-L1 and FcR. The invention also provides a nucleic acid molecule for coding the recombinant fusion protein, an expression vector containing the nucleic acid molecule, a method for preparing the recombinant fusion protein, and a method for treating diseases related to CD47 and/or PD-L1 overexpression by using the recombinant fusion protein.

The present invention relates to a cytokeratin 8/18 complex-specific autoantibody or a fragment comprising an antigen-binding site (paratope) thereof, the use thereof in the diagnosis of breast cancer, a polypeptide having an amino acid sequence of an epitope specifically binding to the autoantibody, a composition for diagnosing breast cancer comprising an agent capable of measuring an expression level of the autoantibody or the fragment comprising an antigen-binding site thereof, a hybridoma cell line producing the autoantibody, and a kit for diagnosing breast cancer comprising the composition of the present invention. Further, the present invention relates to a method for diagnosing breast cancer, comprising the step of detecting the cytokeratin 8/18 complex-specific autoantibody or the fragment comprising the antigen-binding site thereof using the composition of the present invention, and a method for screening a therapeutic agent for breast cancer using the autoantibody.

The present disclosure provides biparatopic antibodies comprising polypeptides that bind to folate receptor alpha (FRα) compositions comprising such biparatopic antibodies. In a specific aspect, the biparatopic antibodies bind to FRα and modulate FRα activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a biparatopic antibody that specifically binds to FRα and modulates FRα activity.

The present disclosure provides a recombinant fusion protein containing an extracellular Ig-like domain of a signal-regulator protein (SIRP), linked via a linker, to a paratope of an Ig-like anti-HER2 antibody at the N-terminus of a heavy chain or a light chain constituting the paratope. The present disclosure also provides a polynucleotide encoding the recombinant fusion protein, an expression vector containing the polynucleotide, a method for producing the recombinant protein and a method for treating a disease caused by over-expression of CD47 and/or HER2.

A method of treating a mammalian subject having hematologic, non-tumorous cancer cells is disclosed. The method comprises the steps of: (A) administering to such a mammalian subject a therapeutically effective amount of a halogenated xanthene, a pharmaceutically acceptable salt or a C₁-C₄ alkyl ester thereof as a first cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable aqueous medium. The mammalian subject is maintained for a period of time sufficient to induce death of hematologic, non-tumorous cancer cells. A contemplated administration is typically repeated. A contemplated treatment method can also be carried out in conjunction with administration to said mammalian subject of a second therapeutically effective amount of a second, differently-acting cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable medium. The second cancer cytotoxic agent can be a small molecule or an intact antibody or paratope-containing portion thereof.

The invention provides a recombinant fused protein. The recombinant fused protein comprises a CD70 antibody or an antibody fragment thereof, wherein at least one complementary position of the CD70 antibody or the antibody fragment thereof is connected with an extracellular Ig-like structural domain of a signal regulatory protein (SIRP) at an N-terminal of a heavy chain or a light chain forming the complementary position through a linker, and the recombinant fused protein can be combined with CD47, the CD70 and FcR at the same time. The invention also provides a nucleic acid molecule coding the recombinant fused protein, an expression vector comprising the nucleic acid molecule, a method for preparing the recombinant fused protein and use of the recombinant fused protein in treatment of diseases associated with CD47 and/or CD70 overexpression.